American Society of Hirudotherapy

Invertebrate compounds acting on the hemostatic mechanism

Review published in Blood Coagul Fibrinolysis (1999)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewSalivary PharmacologyDrug DevelopmentArocha-Piñango CL et al. · Blood Coagul Fibrinolysis, 1999

Abstract

Physiological secretions from some invertebrates have toxic effects on mammalian blood coagulation and fibrinolytic systems. Some of these effects occur because the substances contained in the secretions resemble the components of the hemostatic system. Some of the substances have been characterized, and have been found to have similar molecular weights or sequences, which may indicate a common ancestry. The components can be divided into five groups: antithrombic agents (group I); inhibitors and activators of the prothrombinase complex (group II); substances that affect platelet function (group III); substances that affect the fibrinolytic mechanism (group IV); and a group of miscellaneous agents whose activities are difficult to group together (group V). In group I special mention of the antithrombin agents in Hirudo medicinalis should be made. In group II, the agents affecting the prothrombinase complex are antistasin from Haementeria officinalis, ghilanten from Haementeria Ghiliani and the tick anticoagulant protein from Ornithodoros moubata, a factor V activator/inhibitor from Lonomia achelous and factor II and factor X activators from L. achelous and Lonomia obliqua. Examples of factors which affect platelet function (group III) are glossina from the black fly Glossina morsitans, calin from H. medicinalis, decorsin (a desintegrin) from Macrobdella decorsa, and FAGA from Stichopus japonicus selenka. The first three of these are inhibitors of platelet aggregation, and the last is an inducer. The plasminogen activators (group IV) from the L. achelous caterpillar and Eutriatoma maculata trigger the fibrinolytic system, whereas hementin from H. officinalis and hementerin from Haementeria depressa are directly fibrinolytic. The last group of substances (group V) include those with factor-XIIa-like activity from D. farinae, kallikrein-like activity and a factor XIII degrading enzyme from L. achelous, destabilase from H. medicinalis and prolixin S (nitroforin 2, or anti-factor-IXa) from Rhodnius prolixus. Some of these components have been well characterized, cloned and prepared in recombinant form, and seem to be very promising from the therapeutic point of view.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnimalsBiological FactorsBlood PlateletsFactor VFactor XFactor XaFibrinHematologic AgentsHemostasisHumansInvertebratesThrombin

Summary

Review classifying invertebrate secretions that impair mammalian coagulation and fibrinolysis into five groups, including agents such as antistasin, ghilanten, calin, decorsin, hementin and destabilase, some cloned and prepared recombinantly.

Why This Matters for Hirudotherapy

This review article surveys a wide array of invertebrate-derived physiological secretions that affect the mammalian hemostatic and fibrinolytic systems. It categorizes these biological factors into five groups based on their mechanisms, prominently featuring substances from leeches, including antithrombin agents and calin from Hirudo medicinalis, decorsin from Macrobdella decorsa, and destabilase from H. medicinalis. The abstract notes that some of these components have been well characterized, cloned, and prepared in recombinant form, showing therapeutic promise. This paper is relevant to the American Society of Hirudotherapy because it details the biochemical diversity and pharmacological potential of specific compounds derived from medicinal leeches. However, its scope is broad and covers many non-leech invertebrates.

Citation

Reference (Vancouver style)

Arocha-Piñango CL, Marchi R, Carvajal Z, Guerrero B. Invertebrate compounds acting on the hemostatic mechanism. Blood Coagul Fibrinolysis. 1999;10(2):43-68. doi:10.1097/00001721-199903000-00001. PMID: 10192653

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.